MarketCap
Facebook
X
Telegram
AbbVie Operating Expenses | ABBV
Annual Operating Expenses AbbVie
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | 12.8 B | 18.7 B | 11.6 B | 10.4 B | 10.8 B | 12.1 B | 8.54 B | 8.06 B | 8.51 B | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 18.7 B | 8.06 B | 11.3 B |
Operating Expenses of other stocks in the Biotechnology industry
| Issuer | Operating Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Фармсинтез
LIFE
|
201 M | - | - | - |  Russia |
 |
AbCellera Biologics
ABCL
|
292 M | $ 10.89 | 4.11 % | $ 3.25 B |  Canada |
 |
Ayala Pharmaceuticals
AYLA
|
29.8 M | - | - | $ 7.46 M |  Israel |
 |
Amryt Pharma plc
AMYT
|
109 M | - | - | $ 621 M |  Britain |
 |
Evelo Biosciences
EVLO
|
108 M | - | -14.46 % | $ 27.9 M |  USA |
 |
ASLAN Pharmaceuticals Limited
ASLN
|
55.7 M | - | -14.27 % | $ 1.7 M |  Singapore |
 |
Acorda Therapeutics
ACOR
|
206 M | - | -24.86 % | $ 820 K | USA |
 |
Adaptimmune Therapeutics plc
ADAP
|
141 M | - | -15.15 % | $ 60.3 M | Britain |
 |
Advaxis
ADXS
|
19.6 M | - | -9.65 % | $ 45.9 M | USA |
 |
Abeona Therapeutics
ABEO
|
64.2 M | $ 5.42 | 0.18 % | $ 287 M | USA |
 |
iTeos Therapeutics
ITOS
|
195 M | - | - | $ 411 M | USA |
 |
Galmed Pharmaceuticals Ltd.
GLMD
|
8.51 M | $ 4.63 | 21.05 % | $ 20 M | Israel |
 |
Akouos
AKUS
|
86.8 M | - | 0.23 % | $ 488 M | USA |
 |
Albireo Pharma
ALBO
|
163 M | - | -0.23 % | $ 916 M | USA |
 |
BioXcel Therapeutics
BTAI
|
107 M | $ 0.07 | 9.81 % | $ 855 K | USA |
 |
Allakos
ALLK
|
122 M | - | - | $ 28.6 M | USA |
 |
Cyclerion Therapeutics
CYCN
|
3.21 M | $ 23.52 | 458.67 % | $ 98.9 M | USA |
 |
Lexicon Pharmaceuticals
LXRX
|
101 M | $ 2.0 | 0.3 % | $ 726 M | USA |
 |
Allena Pharmaceuticals
ALNA
|
10.1 M | - | 3.16 % | $ 1.9 M | USA |
 |
Alpine Immune Sciences
ALPN
|
103 M | - | - | $ 2.17 B | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
52.2 M | $ 5.12 | 0.1 % | $ 981 M | Canada |
 |
Ampio Pharmaceuticals
AMPE
|
9.57 M | - | -11.43 % | $ 502 K | USA |
 |
NextCure
NXTC
|
57.6 M | $ 7.0 | 0.55 % | $ 19.9 M | USA |
 |
Aridis Pharmaceuticals
ARDS
|
23.4 K | - | 17.91 % | $ 11.1 M | USA |
 |
Nanobiotix S.A.
NBTX
|
43.4 M | $ 37.01 | 0.27 % | $ 1.77 T |  France |
 |
ACADIA Pharmaceuticals
ACAD
|
708 M | $ 27.83 | 0.32 % | $ 4.69 B | USA |
 |
Axcella Health
AXLA
|
77 M | - | -16.42 % | $ 249 M | USA |
 |
SQZ Biotechnologies Company
SQZ
|
102 M | - | 57.95 % | $ 12.8 M | USA |
 |
Atreca
BCEL
|
98.7 M | - | -11.76 % | $ 5.79 M | USA |
 |
Berkeley Lights
BLI
|
152 M | - | -7.31 % | $ 87 M | USA |
 |
Bellerophon Therapeutics
BLPH
|
22.4 M | - | -74.18 % | $ 955 K | USA |
 |
Achieve Life Sciences
ACHV
|
16.5 M | $ 7.06 | 0.41 % | $ 308 M | USA |
 |
Baudax Bio
BXRX
|
54.6 M | - | 0.59 % | $ 63 K | USA |
 |
Calithera Biosciences
CALA
|
42.1 M | - | -10.95 % | $ 876 K | USA |
 |
CymaBay Therapeutics
CBAY
|
133 M | - | - | $ 3.45 B | USA |
 |
Codiak BioSciences
CDAK
|
92.5 M | - | -55.98 % | $ 2.15 M | USA |
 |
ChemoCentryx
CCXI
|
120 M | - | - | $ 3.74 B | USA |
 |
Avid Bioservices
CDMO
|
26 M | - | - | $ 789 M | USA |
 |
AC Immune SA
ACIU
|
72.9 M | $ 2.76 | 2.6 % | $ 278 M |  Schweiz |
|
Cerevel Therapeutics Holdings
CERE
|
447 M | - | - | $ 7.29 B | USA |
 |
Aclaris Therapeutics
ACRS
|
92.7 M | $ 5.32 | 1.27 % | $ 652 M | USA |
 |
Checkpoint Therapeutics
CKPT
|
56.2 M | - | - | $ 169 M | USA |
 |
ADC Therapeutics SA
ADCT
|
334 M | $ 1.07 | 0.45 % | $ 136 M | Schweiz |
 |
Adial Pharmaceuticals
ADIL
|
7.8 M | $ 4.9 | 0.08 % | $ 3.28 M | USA |
 |
ADMA Biologics
ADMA
|
101 M | $ 9.23 | 0.16 % | $ 2.2 B | USA |
 |
Adaptive Biotechnologies Corporation
ADPT
|
141 M | $ 24.2 | 0.08 % | $ 3.67 B | USA |
 |
Agenus
AGEN
|
46 M | $ 6.94 | 0.73 % | $ 206 M | USA |
 |
Agios Pharmaceuticals
AGIO
|
543 M | $ 33.6 | 0.16 % | $ 1.95 B | USA |